Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Below 50-Day Moving Average of $8.27

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $8.27 and traded as low as $7.55. Voyager Therapeutics shares last traded at $7.59, with a volume of 359,068 shares trading hands.

Analyst Ratings Changes

A number of equities analysts have commented on VYGR shares. Citigroup started coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They issued a “buy” rating and a $16.00 target price for the company. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Guggenheim assumed coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They set a “buy” rating and a $22.00 price objective for the company. Wedbush reduced their price objective on Voyager Therapeutics from $10.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, May 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, May 16th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Voyager Therapeutics Price Performance

The company has a fifty day simple moving average of $8.27 and a 200-day simple moving average of $8.39.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.24. The company had revenue of $19.52 million for the quarter, compared to analysts’ expectations of $10.33 million. Voyager Therapeutics had a negative return on equity of 1.28% and a negative net margin of 2.56%. On average, equities research analysts forecast that Voyager Therapeutics, Inc. will post -1.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VYGR. Farallon Capital Management LLC raised its stake in Voyager Therapeutics by 77.4% during the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after purchasing an additional 1,000,000 shares during the period. Vanguard Group Inc. raised its stake in Voyager Therapeutics by 27.8% during the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after purchasing an additional 702,030 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Voyager Therapeutics in the fourth quarter worth $1,569,000. Hunter Perkins Capital Management LLC acquired a new position in shares of Voyager Therapeutics in the first quarter worth $607,000. Finally, Armistice Capital LLC increased its stake in shares of Voyager Therapeutics by 1.4% in the fourth quarter. Armistice Capital LLC now owns 4,236,000 shares of the company’s stock worth $35,752,000 after acquiring an additional 58,000 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.